Loading…
Compugen Ltd. is projected to rise to $2.81 by 2027, a +17% move from its current price of $2.39. CGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.33 | $2.39 | $2.46 | +0.02% |
| Jul 14 | $2.30 | $2.39 | $2.49 | +0.03% |
| Jul 15 | $2.28 | $2.39 | $2.51 | +0.05% |
| Jul 16 | $2.26 | $2.39 | $2.53 | +0.06% |
| Jul 17 | $2.25 | $2.39 | $2.54 | +0.08% |
| Jul 18 | $2.24 | $2.39 | $2.56 | +0.09% |
| Jul 19 | $2.22 | $2.39 | $2.57 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.22 | $2.39 | $2.57 | +0.11% |
| Week 2 | $2.16 | $2.40 | $2.66 | +0.22% |
| Week 3 | $2.11 | $2.40 | $2.72 | +0.33% |
| Week 4 | $2.07 | $2.40 | $2.78 | +0.44% |
| Week 5 | $2.04 | $2.40 | $2.83 | +0.55% |
| Week 6 | $2.01 | $2.41 | $2.88 | +0.66% |
| Week 7 | $1.99 | $2.41 | $2.92 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Compugen Ltd. is a clinical-stage therapeutic discovery and development company. It engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
The company’s pipeline includes COM701, an immuno-oncology program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, in Phase 1 trials and evaluated as a monotherapy or in combinations such as PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade. It also includes Bapotulimab, a therapeutic antibody targeting ILDR2 in Phase I for naïve head and neck squamous cell carcinoma, and Rilvegostomig, a novel anti-PD-1/TIGIT bispecific antibody in a Phase III study for advanced or metastatic non-small cell lung cancer. The preclinical pipeline covers additional immuno-oncology programs addressing various mechanisms of immune resistance, plus COM503, a high-affinity antibody blocking the interaction between IL-18 binding protein and IL-18.
The company has collaboration with Bristol-Myers Squibb to evaluate COM701 with Opdivo in advanced solid tumors, a license with AstraZeneca for bi-specific/multi-specific immuno-oncology products, and a collaboration with Gilead Sciences for COM503 and other products. It was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen Ltd. (CGEN) is a clinical-stage biotechnology company focused on immuno-oncology with a diversified pipeline. It currently trades at $2.47 per share and has a market capitalization of $233.62M.
The stock is ranked 3723 by market cap, reflecting its size within the broader market landscape. Near-term metrics show a mixed-to-bullish setup given recent price levels and expected activity.
A major floor 34.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.0% below — buyers have tended to step in here.
The nearest ceiling, 16.3% above — a clean break opens room to run.
A major ceiling 33.8% above — clearing it would confirm fresh momentum.
Key CGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.40 | Sell | $2.38 | Buy |
| MA 10 | $2.28 | Buy | $2.31 | Buy |
| MA 20 | $2.15 | Buy | $2.26 | Buy |
| MA 50 | $2.42 | Sell | $2.32 | Buy |
| MA 100 | $2.35 | Buy | $2.27 | Buy |
| MA 200 | $2.02 | Buy | $2.11 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.71 | Neutral |
| Stoch RSI (14) | 78.22 | Neutral |
| CCI (20) | 113.80 | Buy |
| Williams %R (14) | -17.39 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 18.32 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 82.61 | Sell |
| TRIX (15) | -0.37 | Sell |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 73.09 | Sell |
| Momentum (10) | 0.37 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 2.49 | Sell |
| ADX (14) | 21.09 | Buy |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bullish in sentiment. RSI14 sits at 60, with the 50-day simple moving average at $2.43 and the 200-day simple moving average at $2.02, placing the stock near key moving-average support and resistance levels. Immediate support is reported at $1.96 and resistance at $2.78, with a 30-day trading range between $2.06 and $2.96.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.52 | $2.39 | $3.08 | 0% | Neutral | |
| $2.23 | $2.81 | $3.73 | +17% | Neutral | |
| $2.30 | $2.98 | $4.12 | +25% | Bullish | |
| $3.00 | $3.98 | $5.66 | +66% | Bullish | |
| $3.46 | $4.68 | $6.81 | +96% | Bullish | |
| $3.38 | $4.65 | $6.93 | +95% | Bullish | |
| $3.65 | $5.11 | $7.76 | +114% | Bullish | |
| $3.70 | $5.27 | $8.14 | +120% | Bullish | |
| $3.93 | $5.69 | $8.92 | +138% | Bullish | |
| $4.94 | $7.26 | $11.57 | +204% | Bullish | |
| $5.92 | $9.31 | $15.78 | +290% | Bullish | |
| $12.31 | $21.77 | $40.40 | +811% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.52 | $2.39 | $2.79 | +0.00% |
| August 2026 | $1.99 | $2.35 | $2.85 | -1.57% |
| September 2026 | $2.04 | $2.42 | $2.97 | +3.06% |
| October 2026 | $2.01 | $2.40 | $2.98 | -0.82% |
| November 2026 | $1.98 | $2.38 | $2.97 | -1.15% |
| December 2026 | $2.03 | $2.45 | $3.08 | +3.25% |
Click any year to see its month-by-month CGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CGEN price prediction for 2026 points to an average of $2.39 (low $1.52, high $3.08) — a potential gain of 0% on today's $2.39. Price action looks broadly range-bound.
In 2027, CGEN is projected to trade between $2.23 and $3.73, averaging $2.81 — a potential gain of +17% from today's $2.39. That is up +17% on the projected 2026 average. A consolidation phase looks the most probable path here.
Compugen Ltd.'s 2028 outlook centres on $2.98, within a $2.30 to $4.12 range. That is up +6% on the projected 2027 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2029, CGEN could reach as high as $5.66, with a base case around $3.98 and support toward $3.00 — roughly +66% from $2.39. Buyers look set to stay in control over this stretch.
Expect CGEN to range from $3.46 to $6.81 through 2030. The $4.68 average target implies a +96% move from current prices. That is up +18% on the projected 2029 average. Momentum favours further upside here.
The CGEN price prediction for 2031 points to an average of $4.65 (low $3.38, high $6.93) — a potential gain of +95% on today's $2.39. Buyers look set to stay in control over this stretch.
In 2032, CGEN is projected to trade between $3.65 and $7.76, averaging $5.11 — a potential gain of +114% from today's $2.39. That is up +10% on the projected 2031 average. Momentum favours further upside here.
Compugen Ltd.'s 2033 outlook centres on $5.27, within a $3.70 to $8.14 range. That is up +3% on the projected 2032 average. That marks a +120% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CGEN could reach as high as $8.92, with a base case around $5.69 and support toward $3.93 — roughly +138% from $2.39. Momentum favours further upside here.
Expect CGEN to range from $4.94 to $11.57 through 2035. The $7.26 average target implies a +204% move from current prices. That is up +28% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CGEN price prediction for 2040 points to an average of $9.31 (low $5.92, high $15.78) — a potential gain of +290% on today's $2.39. Momentum favours further upside here.
In 2050, CGEN is projected to trade between $12.31 and $40.40, averaging $21.77 — a potential gain of +811% from today's $2.39. That is up +134% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CGEN today (≈ 418.410042 CGEN) could be worth
$9,108.09
+$8,108.09 (+811%) by 2050 · US Dollar
Based on the average projected CGEN price of $21.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGENwould be worth at today's price.
$1,000 invested in CGEN on Jul 10, 2025 (≈ 591.715956 CGEN) would be worth
$1,414.2
+$414.2 (+41.4%) today · 1.41× · US Dollar
Based on a CGEN entry price of $1.69 vs. today's $2.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.28 | $1,048.25 | +4.8% |
| 1 month ago | $1.96 | $1,219.39 | +21.9% |
| 3 months ago | $2.58 | $926.36 | -7.4% |
| 6 months ago | $1.98 | $1,207.07 | +20.7% |
| 1 year ago | $1.69 | $1,414.2 | +41.4% |
| All time (5.0y) ago | $7.45 | $320.81 | -67.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGEN forecast.
Our base-case forecast reaches $4.80 around 2032.
Implied market cap at $4.80: $454.01M
The multi-year forecast outlines meaningful upside from the current level. The 2026 forecast shows an average price of $2.47 with a min of $1.52 and a max of $3.25, and a 0% ROI, indicating little expected gain that year. By 2027 the average is projected to $3.07 with a 24.2% ROI, rising further to an average of $3.43 in 2028 (38.7% ROI) and $4.68 in 2029 (89.3% ROI).
In 2030 the forecast calls for an average of $5.55 (ROI 124.8%), expanding to $5.63 in 2031 (ROI 127.8%), and $6.33 in 2032 (ROI 156.2%). By 2033 the average reaches $6.65 (ROI 169.2%), and by 2034 it estimates $7.40 (ROI 199.4%). The long horizon shows substantial upside with 2035 averaging $9.66 (ROI 290.9%), 2040 averaging $12.89 (ROI 421.8%), and 2050 averaging $31.49 (ROI 1174.8%).
These figures imply a bullish long-term trajectory with increasingly wide upside ranges, but they remain estimates and subject to market, clinical, and regulatory risks.
Tap a question to reveal the answer.
2030 forecast: average $5.55, min $4.11, max $8.09; ROI 124.8%; sentiment Bullish.
Long-term forecasts show increasing upside with 2027–2050 averages rising to $3.07, $3.43, $4.68, $5.55, and beyond, with ROIs up to 124.8% by 2030 and much higher later, though near-term results include a 2026 average of $2.47 and a 0% ROI. The outlook is bullish in the long term but carries uncertainty and no guarantees.
Yes. The forecast shows a 2033 average of $6.65 and a max of $10.27, a 2034 max of $11.61, and a 2035 max of $15.38, indicating that a $10 level is within the projected range in the coming years.
Current price is $2.47 and market cap is $233.62M. The stock is ranked 3723 by market cap.
The 2050 forecast shows an average price of $31.49 with a min of $17.81 and a max of $58.43, and ROI of 1174.8%, indicating a potential very large upside if the long-term estimates materialize.
Compugen Ltd. Community Discussion
0Share your Compugen Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.